Incidence and survival of sebaceous carcinoma in the United States

Published:October 06, 2016DOI:


      Information on risk factors, epidemiology, and clinical characteristics of sebaceous carcinoma (SC) is limited.


      We sought to analyze trends in SC in the United States from 2000 through 2012.


      We used data from the 18 registries of the Surveillance, Epidemiology, and End Results (SEER) Program from 2000 to 2012 to calculate the cause of death, relative frequencies/incidences, 5-/10-year Kaplan-Meier survival, hazard ratios, and incidence rates for SC. Each parameter was analyzed by age, location of occurrence (ocular/extraocular), race, sex, and SEER registry.


      Overall incidence was 0.32 (male) and 0.16 (female) per 100,000 person-years. Incidence significantly increased, primarily because of an increase among men. Incidence among whites was almost 3 times the rate among non-whites. Male sex (P < .0001), black race (P = .01), and extraocular anatomic location (P < .0001) were associated with significantly higher all-cause mortality. However, overall case-specific mortality for SC decreased significantly.


      Underregistration of patients in SEER registries, lack of verification of individual diagnoses, and low levels of staging data because of low stage-classification rate are limitations.


      The overall incidence of SC is increasing significantly. Male sex, black race, and extraocular occurrences are associated with significantly greater mortality.

      Key words

      Abbreviations used:

      APC (annual percent change), CI (confidence interval), DFSP (dermatofibrosarcoma protuberans), HR (hazard ratio), SC (sebaceous carcinoma), SEER (Surveillance, Epidemiology, and End Results)
      To read this article in full you will need to make a payment
      AAD Member Login
      AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Shields J.A.
        • Demirci H.
        • Marr B.P.
        • Eagle R.C.
        • Shields C.L.
        Sebaceous carcinoma of the ocular region: a review.
        Surv Ophthalmol. 2005; 50: 103-122
        • Nelson B.R.
        • Hamlet K.R.
        • Gillard M.
        • Railan D.
        • Johnson T.M.
        Sebaceous carcinoma.
        J Am Acad Dermatol. 1995; 33: 1-15
        • Bailet J.W.
        • Zimmerman M.C.
        • Arnstein D.P.
        • Wollman J.S.
        • Mickel R.A.
        Sebaceous carcinoma of the head and neck: case report and literature review.
        Arch Otolaryngol Head Neck Surg. 1992; 118: 1245-1249
        • Dasgupta T.
        • Wilson L.D.
        • Yu J.B.
        A retrospective review of 1349 cases of sebaceous carcinoma.
        Cancer. 2009; 115: 158-165
        • Ni C.
        • Guo B.K.
        Pathologic classification of meibomian gland carcinomas of eyelids: clinical and pathologic study of 156 cases.
        Chin Med J (Engl). 1979; 92: 671-676
        • Abdi U.
        • Tyagi N.
        • Maheshwari V.
        • Gogi R.
        • Tyagi S.P.
        Tumours of eyelid: a clinicopathologic study.
        J Indian Med Assoc. 1996; 94: 405-409
        • Ni C.
        • Searl S.S.
        • Kuo P.K.
        • Chu F.R.
        • Chong C.S.
        • Albert D.M.
        Sebaceous cell carcinomas of the ocular adnexa.
        Int Ophthalmol Clin. 1982; 22: 23-61
        • Dores G.M.
        • Curtis R.E.
        • Toro J.R.
        • Decesa S.S.
        • Fraumeni J.J.
        Incidence of cutaneous sebaceous carcinoma and risk of associated neoplasms: insight into Muir-Torre syndrome.
        Cancer. 2008; 113: 3372-3381
        • Thomas W.W.
        • Fritsch V.A.
        • Lentsch E.J.
        Population-based analysis of prognostic indicators in sebaceous carcinoma of the head and neck.
        Laryngoscope. 2013; 123: 2165-2169
        • Tryggvason G.
        • Bayon R.
        • Pagedar N.A.
        Epidemiology of sebaceous carcinoma of the head and neck: implications for lymph node management.
        Head Neck. 2012; 34: 1765-1768
      1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER limited-use data (1973-2012). Bethesda (MD): National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. Based on the November 2014 submission. Available at: Accessed January 5, 2015.

      2. Fritz A. Percy C. Jack A. Sobin L.H. Parkin M.D. International Classification of Diseases for Oncology. 3rd ed. World Health Organization, Geneva (Switzerland)2000
      3. Surveillance, Epidemiology, and End Results: SEER*Stat 8.1.5. Available at: Accessed January 5, 2015.

        • Tiwari R.C.
        • Clegg L.X.
        • Zou Z.
        Efficient interval estimation for age-adjusted cancer rates.
        Stat Methods Med Res. 2006; 15: 547-569
        • Ely J.W.
        • Dawson J.D.
        • Lemke J.H.
        • Rosenberg J.
        An introduction to time-trend analysis.
        Infect Control Hosp Epidemiol. 1997; 18: 267-274
        • Margo C.E.
        • Mulla Z.D.
        Malignant tumors of the eyelid: a population-based study of non-basal cell and non-squamous cell malignant neoplasms.
        Arch Ophthalmol. 1998; 116: 195-219
        • Kreicher K.L.
        • Kurlander D.E.
        • Gittleman H.R.
        • Barnholtz-Sloan J.S.
        • Bordeaux J.S.
        Incidence and survival of primary dermatofibrosarcoma protuberans in the United States.
        Dermatol Surg. 2016; 42: S24-S31
        • Kosary C.L.
        • Altekruse S.F.
        • Ruhl J.
        • Lee R.
        • Dickie L.
        Clinical and prognostic factors for melanoma of the skin using SEER registries: collaborative stage data collection system, version 1 and version 2.
        Cancer. 2014; 120: 3807-3814
        • Mayer J.E.
        • Swetter S.M.
        • Fu T.
        • Geller A.C.
        Screening, early detection, education, and trends for melanoma: current status (2007-2013) and future directions: part II. Screening, education, and future directions.
        J Am Acad Dermatol. 2014; 71: 611.e1-611.e10
        • Torres J.S.
        • Amorim A.C.
        • Hercules F.M.
        • Kac B.K.
        Giant extraocular sebaceous carcinoma: case report and a brief review of a literature.
        Dermatol Online J. 2012; 18: 7
        • Shalin S.C.
        • Lyle S.
        • Calonje E.
        • Lazar A.J.F.
        Sebaceous neoplasia and the Muir-Torre syndrome: important connections with clinical implications.
        Histopathology. 2010; 56: 133-147
        • DeSantis C.E.
        • Lin C.C.
        • Mariotto A.B.
        • et al.
        Cancer treatment and survivorship statistics, 2014.
        CA Cancer J Clin. 2014; 64: 252-271
        • Weinstock M.A.
        • Gardstein B.A.
        Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality.
        Am J Public Health. 1999; 89: 1240-1244
        • Seiffert J.
        Underreporting of melanoma.
        J Natl Cancer Inst. 1992; 84: 289
        • Bolognia J.L.
        • Headley A.
        • Fine J.
        • Berwick M.
        Histologic evaluation of pigmented lesions in Connecticut and its influence on the reporting of melanoma.
        J Am Acad Dermatol. 1992; 26: 198-202